The tweet was deleted by the author.
But we saved everything 🙂.
Vir Biotechnology has announced new data from its Phase 2 SOLSTICE trial demonstrating sustained suppression of hepatitis D virus (HDV) at Week 96.
The results, shared during the final day of EASL2026, underscore the potential progress in therapies for chronic hepatitis D (CHD), a field with significant unmet medical need. The company highlighted coverage of its findings in the American Journal of Managed Care. Vir Biotechnology expressed appreciation for ongoing engagement within the hepatology community as the SOLSTICE study progresses.
View post on X Loading...
Vir Biotechnology recently presented data on the effects of body mass index in chronic hepatitis delta patients from its Phase 2 SOLSTICE study at EASL2026 here. Earlier this year, CEO Marianne De Backer participated in a live fireside chat at the Bank of America Securities 2026 Healthcare Conference here. The company continues to update stakeholders on its clinical progress.